Wall Street analysts predict that Foundation Medicine Inc (NASDAQ:FMI) will report earnings of ($1.00) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Foundation Medicine’s earnings, with estimates ranging from ($1.15) to ($0.86). Foundation Medicine reported earnings per share of ($1.02) in the same quarter last year, which suggests a positive year over year growth rate of 2%. The company is scheduled to announce its next quarterly earnings report on Wednesday, February 28th.

According to Zacks, analysts expect that Foundation Medicine will report full year earnings of ($4.44) per share for the current financial year, with EPS estimates ranging from ($4.60) to ($4.31). For the next fiscal year, analysts forecast that the business will report earnings of ($3.81) per share, with EPS estimates ranging from ($4.30) to ($3.13). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Foundation Medicine.

Foundation Medicine (NASDAQ:FMI) last released its earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.06) by $0.16. The firm had revenue of $42.66 million for the quarter, compared to the consensus estimate of $37.99 million. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. The company’s revenue was up 45.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.90) EPS.

Several equities research analysts have recently commented on FMI shares. Zacks Investment Research lowered shares of Foundation Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. BidaskClub lowered shares of Foundation Medicine from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $45.33.

Foundation Medicine (NASDAQ FMI) opened at $63.80 on Tuesday. The company has a quick ratio of 2.03, a current ratio of 2.24 and a debt-to-equity ratio of 0.47. Foundation Medicine has a one year low of $17.10 and a one year high of $70.75.

In related news, COO Steven J. Kafka sold 3,201 shares of Foundation Medicine stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $38.80, for a total transaction of $124,198.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jason Ryan sold 21,726 shares of the business’s stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $61.26, for a total value of $1,330,934.76. Following the completion of the transaction, the chief financial officer now directly owns 55,639 shares of the company’s stock, valued at $3,408,445.14. The disclosure for this sale can be found here. Insiders sold 84,057 shares of company stock worth $4,588,768 in the last quarter. 2.70% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in the business. Chevy Chase Trust Holdings Inc. lifted its holdings in Foundation Medicine by 1.1% in the third quarter. Chevy Chase Trust Holdings Inc. now owns 1,059,141 shares of the company’s stock valued at $42,572,000 after acquiring an additional 11,934 shares during the period. Discovery Group I LLC increased its position in shares of Foundation Medicine by 0.9% in the third quarter. Discovery Group I LLC now owns 836,986 shares of the company’s stock valued at $33,647,000 after buying an additional 7,181 shares in the last quarter. Oppenheimer & Co. Inc. increased its position in shares of Foundation Medicine by 5.8% in the third quarter. Oppenheimer & Co. Inc. now owns 723,480 shares of the company’s stock valued at $29,084,000 after buying an additional 39,390 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Foundation Medicine by 8.2% in the second quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock valued at $25,096,000 after buying an additional 47,843 shares in the last quarter. Finally, Lord Abbett & CO. LLC increased its position in shares of Foundation Medicine by 146.0% in the second quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock valued at $23,024,000 after buying an additional 343,770 shares in the last quarter. 33.44% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Foundation Medicine Inc (FMI) Expected to Post Earnings of -$1.00 Per Share” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/12/foundation-medicine-inc-fmi-expected-to-post-earnings-of-1-00-per-share.html.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Get a free copy of the Zacks research report on Foundation Medicine (FMI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.